Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions

Details for Australian Patent Application No. 2004279336 (hide)

Owner Allergan, Inc

Inventors Gil, Daniel W.; Donello, John E.

Agent Davies Collison Cave

Pub. Number AU-A-2004279336

PCT Pub. Number WO2005/034998

Priority 10/881,761 30.06.04 US; 60/502,327 12.09.03 US

Filing date 19 August 2004

Wipo publication date 21 April 2005

International Classifications

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 31/135 (2006.01) - having aromatic rings, e.g. methadone

A61K 31/4168 (2006.01)

A61K 31/498 (2006.01) - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61K 31/517 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Event Publications

30 March 2006 PCT application entered the National Phase

  PCT publication WO2005/034998 Priority application(s): WO2005/034998

26 May 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004279344-Apparatus for, and method of, determining the condition of a patient's heart

2004279333-Methods for identifying improved, nonsedating alpha-2 agonists